Table of contents

  • Preliminary material
    • Title and verso pages
    • Contents
    • Acknowledgments
    • Abbreviations
    • Symbols
    • A summary of alcohol and other drug treatment in 2009–10
  • Body section
    • 1 Introduction
      • Definitions of terms used in this report
      • 1.1 How are the data collected?
      • 1.2 What's included?
        • 1.2.1 Agencies and clients included
        • 1.2.2 Agencies and clients excluded
      • 1.3 Important issues that explain the data
        • 1.3.1 Clients are not counted
        • 1.3.2 Funding source cannot be differentiated
        • 1.3.3 Covering of Indigenous substance use services is limited
        • 1.3.4 Implementation makes a difference
      • 1.4 Data issues specific to the 2009–10 year
      • 1.5 Explanatory notes
    • 2 Treatment agencies–what sector and where are the treatment agencies?
      • 2.1 Service sector
      • 2.2 Locations
      • 2.3 Treatment types reporting from different geographical locations
    • 3 Clients – who uses alcohol and other drug treatment services?
      • 3.1 Own or other's drug use
        • 3.1.1 Across Australia
        • 3.1.2 Age and sex
      • 3.2 Indigenous Australians
        • 3.2.1 Indigenous clients in the AODTS-NMDS collection
        • 3.2.2 Care provided by OATSIH-funded substance use-specific services
      • 3.3 Country of birth and preferred language
    • 4 Drugs of concern–what drugs do people seek treatment for?
      • 4.1 Principal drugs of concern
        • 4.1.1 Principal drugs of concern across Australia
        • 4.1.2 Principal drugs of concern over time
        • 4.1.3 Age and principal drug of concern
        • 4.1.4 Sex and principal drugs of concern
        • 4.1.5 Indigenous Australians and principal drug of concern
      • 4.2 Individual principal drug of concern profiles
        • 4.2.1 Alcohol
          • Patterns of use in Australia
          • Drug profile
          • Client profile
          • Treatment profile
        • 4.2.2 Cannabis
          • Patterns of use in Australia
          • Drug profile
          • Client profile
          • Treatment profile
        • 4.2.3 Heroin
          • Patterns of use in Australia
          • Drug profile
          • Client profile
          • Treatment profile
        • 4.2.4 Amphetamines
          • Patterns of use in Australia
          • Drug profile
          • Client profile
          • Treatment profile
        • 4.2.5 Benzodiazepines
          • Patterns of use in Australia
          • Drug profile
          • Client profile
          • Treatment profile
        • 4.2.6 Ecstasy
          • Patterns of use in Australia
          • Drug profile
          • Client profile
          • Treatment profile
        • 4.2.7 Cocaine
          • Patterns of use in Australia
          • Drug profile
          • Client profile
          • Treatment profile
      • 4.3 All drugs of concern
    • 5 Treatment – what treatments do people receive?
      • 5.1 Main treatment
        • 5.1.1 Main treatment types across Australia
        • 5.1.2 Main treatment types over time
        • 5.1.3 Aboriginal and Torres Strait Islander people and treatment programs
        • 5.1.4 Reasons for leaving treatment
      • 5.2 Specific main treatment types
        • 5.2.1 Counselling
          • Principal drug profile
          • Client profile
          • Treatment profile
        • 5.2.2 Withdrawal management (detoxification)
          • Principal drug profile
          • Client profile
          • Treatment profile
        • 5.2.3 Assessment only
          • Principal drug profile
          • Client profile
          • Treatment profile
        • 5.2.4 Information and education only
          • Principal drug profile
          • Client profile
          • Treatment profile
        • 5.2.5 Support and case management only
          • Principal drug profile
          • Client profile
          • Treatment profile
        • 5.2.6 Rehabilitation
          • Principal drug profile
          • Client profile
          • Treatment profile
        • 5.2.7 Other main treatment types
          • Principal drug profile
          • Client profile
          • Treatment profile
      • 5.3 Additional treatments
      • 5.4 National Opioid Pharmacotherapy Statistics Annual Data Collection 2010
        • 5.4.1 Number of clients receiving pharmacotherapy treatment
      • 5.5 Opioid pharmacotherapy treatment in prison health services 2010
    • 6 Hospital treatment – what drug-related diagnoses do people go to hospital for?
      • 6.1 Drug-related hospital separations in 2009–10
        • 6.1.1 Drugs associated with hospital separations
        • 6.1.2 Hospital separations by sex
        • 6.1.3
        • 6.1.3 Hospital separations by age
        • 6.1.4 Hospital separations by socioeconomic status
        • 6.1.5 Hospital separations among Indigenous Australians
        • 6.1.6 Public versus private hospitals
      • 6.2 Hospital separation trends
    • 7 Collection methods and data quality – how are the data collected?
      • 7.1 Collection method and data included
      • 7.2 Comprehensiveness of the data
        • 7.2.1 Australian Government data
        • 7.2.2 Data quality
      • 7.3 Policy and administrative features in each jurisdiction
      • 7.4 Data quality considerations for other collections
  • End matter
    • Appendix 1: About the collection
      • Responsibility for the collection
      • Government health authorities
      • Alcohol and other drug treatment agencies
      • AIHW
      • Using AODTS–NMDS Data
    • Appendix 2: Data elements in the AODTS NMDS for 2009–10
    • Appendix 3: Detailed tables
      • Agency tables
      • Client profile tables
      • Drugs of concern tables
      • Treatment program tables
      • Hospital separation tables
    • Appendix 4: Australian Standard Geographical Classification
    • Appendix 5: Australian Standard Classification of Drugs of Concern (ASCDC)
      • 1 ANALGESICS
        • 11 Organic Opiate Analgesics
        • 12 Semisynthetic Opioid Analgesics
        • 13 Synthetic Opioid Analgesics
        • 14 Non Opioid Analgesics
      • 2 SEDATIVES AND HYPNOTICS
        • 21 Alcohols
        • 22 Anaesthetics
        • 23 Barbiturates
        • 24 Benzodiazepines
        • 29 Other Sedatives and Hypnotics
      • 3 STIMULANTS AND HALLUCINOGENS
        • 31 Amphetamines
        • 32 Cannabinoids
        • 33 Ephedra Alkaloids
        • 34 Phenethylamines
        • 35 Tryptamines
        • 36 Volatile Nitrates
        • 39 Other Stimulants and Hallucinogens
      • 4 ANABOLIC AGENTS AND SELECTED HORMONES
        • 41 Anabolic Androgenic Steroids
        • 42 Beta Agonists
        • 43 Peptide Hormones, Mimetics and Analogues
        • 49 Other Anabolic Agents and Selected Hormones
      • 5 ANTIDEPRESSANTS AND ANTIPSYCHOTICS
        • 51 Monoamine Oxidase Inhibitors
        • 52 Phenothiazines
        • 53 Serotonin Reuptake Inhibitors
        • 54 Thioxanthenes
        • 55 Tricyclic Antidepressants
        • 59 Other Antidepressants and Antipsychotics
      • 6 VOLATILE SOLVENTS
        • 61 Aliphatic Hydrocarbons
        • 62 Aromatic Hydrocarbons
        • 63 Halogenated Hydrocarbons
        • 69 Other Volatile Solvents
      • 9 MISCELLANEOUS DRUGS OF CONCERN
        • 91 Diuretics
        • 92 Opioid Antagonists
        • 99 Other Drugs of Concern
    • Appendix 6: Alcohol and other drug treatment provided by services funded to assist Aboriginal and Torres Strait Islander people
      • Substance use-specific services
        • Substance use treatment and assistance
          • Substances as a specifically targeted program
          • Substances on an individual client basis
    • Appendix 7: Mapping of ICD-10-AM codes to ASCDC output categories
    • References
    • List of tables
    • List of figures
    • List of boxes